drugset / Trial / NCT02288312

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

NCT02288312

Phase 1 Completed 18 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.

Timeline

Start
2007-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 400 mg Oral
Subject Eslicarbazepine acetate Unknown 800 mg Oral

Indications